Experimental Nuclear Medicine Meets Tumor Biology

Personalized treatment of cancer patients demands specific and validated biomarkers for tumor diagnosis and therapy. The development and validation of such require translational preclinical models that recapitulate human diseases as accurately as possible. Moreover, there is a need for convergence o...

Full description

Saved in:
Bibliographic Details
Published inPharmaceuticals (Basel, Switzerland) Vol. 15; no. 2; p. 227
Main Authors Balber, Theresa, Tran, Loan, Benčurová, Katarína, Raitanen, Julia, Egger, Gerda, Mitterhauser, Markus
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 14.02.2022
MDPI
Subjects
Antigens
biomarker imaging
Biomarkers
cancer biomarkers
Cancer therapies
Disease
in vitro models
Ligands
Magnetic resonance imaging
molecular imaging
molecular pathology
Nuclear medicine
Patients
Prostate cancer
Radiation
Review
Tomography
tracer development
animal models
in vitro models
biomarker imaging
cancer biomarkers
molecular imaging
molecular pathology
tracer development
Online AccessGet full text

Cover

More Information
Summary:Personalized treatment of cancer patients demands specific and validated biomarkers for tumor diagnosis and therapy. The development and validation of such require translational preclinical models that recapitulate human diseases as accurately as possible. Moreover, there is a need for convergence of different (pre)clinical disciplines that openly share their knowledge and methodologies. This review sheds light on the differential perception of biomarkers and gives an overview of currently used models in tracer development and approaches for biomarker discovery.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1424-8247
1424-8247
DOI:10.3390/ph15020227